Decoding 4 Analyst Evaluations For Altimmune
Portfolio Pulse from Benzinga Insights
Four analysts have provided ratings for Altimmune (NASDAQ:ALT) over the past three months, with three bullish and one somewhat bullish. The average 12-month price target is $19.25, with a high of $25.00 and a low of $12.00. Altimmune faces challenges with a revenue decline of -16.67% and a net margin of -492800.0%, but maintains a low debt-to-equity ratio of 0.01.
August 22, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune has received mostly bullish ratings from analysts, with an average price target of $19.25. Despite facing revenue and profitability challenges, the company maintains a low debt-to-equity ratio.
The bullish sentiment from analysts, reflected in the price targets, suggests a positive outlook for Altimmune's stock. However, the company's financial challenges, such as revenue decline and low net margin, may temper this optimism. The low debt-to-equity ratio is a positive factor, indicating conservative financial management.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100